Upcoming Studies
Novartis study CKJX839D12302
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovascular events in high-risk primary prevention patients (VICTORION-1 PREVENT)
This study started enrolling in Autumn 2023 and has now enrolled 14,000 participants in over 45 countries
20/12/2024
Nova 301 Trial
Join the Nova 301 Trial to find out if we can protect people 60 years of age or older against norovirus stomach bug symptoms
Enrolling Adults 60+: Help to see if we can protect people against symptoms caused by the norovirus stomach bug with an investigational mRNA vaccine
18/12/2024
